Baseline visual field findings in the idiopathic intracranial hypertension treatment trial (IIHTT)

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 5, 2014, Pages 3200-3207

  Keltner, John L ^a   Johnson, Chris A ^b   Cello, Kimberly E ^a   Wall, Michael ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Intracranial idiopathic hypertension; Optic neuropathy; Quality control; Visual fields

Indexed keywords

ADULT; ARTICLE; CEREBROSPINAL FLUID; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE FIBER; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; TEST RETEST RELIABILITY; VISUAL FIELD;

INTRACRANIAL IDIOPATHIC HYPERTENSION; OPTIC NEUROPATHY; QUALITY CONTROL; VISUAL FIELDS;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NERVE FIBERS; PSEUDOTUMOR CEREBRI; REPRODUCIBILITY OF RESULTS; VISUAL FIELD TESTS; VISUAL FIELDS; YOUNG ADULT;

EID: 84901417538     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14243     Document Type: Article

References (45)

1. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain. 1991;114:155-180.
2. Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri: follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol. 1982;39:461-474.
3. Sorenson PS, Krogsaa B, Gjerris F. Clinical course and prognosis of pseudotumor cerebri. A prospective study of 24 patients. Acta Neurol Scand. 1988;77:164-172.
4. Wall M, George D. Visual loss in pseudotumor cerebri: incidence and defects related to visual field strategy. Arch Neurol. 1987;44:170-175.
5. Lee AG, Wall M. Papilledema: are we any nearer to a consensus on pathogenesis and treatment? Curr Neurol Neurosci Rep. 2012;12:334-339.
6. Wall M, Kupersmith MJ, Kieburtz KD, et al. The Idiopathic Intracranial Hypertension Treatment Trial: clinical profile at baseline. JAMA Neurol. In press.
7. Friedman DI, McDermott MP, Kieburtz K, et al. The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT): design considerations and methods. J Neuroophthalmol. In press.
8. Smith JL. Whence pseudotumor cerebri? J Clin Neurooph-thalmol. 1985;5:55-56.
9. Friedman DI, Rausch EA. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology. 2002; 58:1551-1553.
10. Bengtsson B, Heijl A. False-negative responses in glaucoma perimetry: indicators of patient performance or test reliability? Am J Ophthalmol. 2000;130:689.
11. Bengtsson B, Heijl A. False-negative responses in glaucoma perimetry: indicators of patient performance or test reliability? Invest Ophthalmol Vis Sci. 2000;41:2201-2204.
12. Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW; For the Optic Neuritis Study Group. Visual field profile of optic neuritis. A final follow-up report from the Optic Neuritis Treatment Trial from baseline through 15 years. Arch Ophthalmol. 2010;128:330-337.
13. Keltner JL, Johnson CA, Cello KE, et al.; For the OHTS Study Group. Classification of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2003;121: 643-650.
14. Bosworth CF, Sample PA, Johnson CA, Weinreb RN. Current practice with standard automated perimetry. Semin Ophthal-mol. 2000;15:172-181.
15. Aulhorn E, Harms H. Early visual field defects in glaucoma. In: Twentieth International Congress of Ophthalmology. Munich: S. Karger; 1967:151-186.
16. Drance SM. Doyne Memorial Lecture, 1975. Correlation of optic nerve and visual field defects in simple glaucoma. Trans Ophthalmol Soc U K. 1975;95:288-296.
17. Aulhorn E, Karmeyer H. Frequency distribution in early glaucomatous visual field defects. In: Second International Visual Field Symposium. Tubingen: The Hague; 1976:75-83.
18. Johnson CA, Keltner JL. Computer analysis of visual field loss and optimization of automated perimetric test strategies. Ophthalmology. 1981;88:1058-1065.
19. Hart WM, Becker B. The onset and evolution of glaucomatous visual field defects. Ophthalmology. 1982;89:268-279.
20. Flanagan JG, Wild JM, Barnes DA, Gilmartin BA, Good PA, Crews SJ. The qualitative comparative analysis of the visual field using computer assisted, semi-automated and manual instrumentation: III. Clinical analysis. Doc Ophthalmol. 1984; 58:341-350.
21. Henson DB, Hobley A. Frequency distribution of early glaucomatous visual field defects. Am J Optom Physiol Opt. 1986;63:455-461.
22. Asman P, Heijl A, Olsson J, Rootzen H. Spatial analyses of glaucomatous visual fields; a comparison with traditional visual field indices. Acta Ophthalmol (Copenh). 1992;70:679-686.
23. Mutlukan E, Keating D. Visual field interpretation with a personal computer based neural network. Eye. 1994;8:321-323.
24. Spenceley SE, Henson DB, Bull DR. Visual field analysis using artificial neural networks. Ophthalmic Physiol Opt. 1994;14: 239-248.
25. Brusini P. Clinical use of a new method for visual field damage classification in glaucoma. Eur J Ophthalmol. 1996;6:402-407.
26. Henson DB, Spenceley SE, Bull DR. Spatial classification of glaucomatous visual field loss. Br J Ophthalmol. 1996;80:526-531.
27. Hilton S, Katz J, Zeger S. Classifying visual field data. Stat Med. 1996;15:1349-1364.
28. Anton A, Maquet JA, Mayo A, Tapia J, Pastor JC. Value of logistic discriminant analysis for interpreting initial visual field defects. Ophthalmology. 1997;104:525-531.
29. Kocak I, Zulauf M, Hendrickson P, Stumpfig D. Evaluation of the Brusini glaucoma staging system for follow-up in glaucoma. Eur J Ophthalmol. 1997;7:345-350.
30. Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis: the experience of the optic neuritis treatment trial. Arch Ophthalmol. 1993;111:231-234.
31. Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis: one-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1994;112:946-953.
32. Gardiner SK, Johnson CA, Cioffi GA. Evaluation of the structure-function relationship in glaucoma. Invest Ophthal-mol Vis Sci. 2005;46:3712-3717.
33. Heijl A, Lundqvist L. The frequency distribution of earliest glaucomatous visual field defects documented by automatic perimetry. Acta Ophthalmol (Copenh). 1984;62:658-664.
34. Henson DB, Hobley AJ. Frequency distribution of early glaucomatous visual field defects. Am J Optom Physiol Opt. 1986;63:455-461.
35. Grehn F, Knorr-Held S, Kommerell G. Glaucomatouslike visual field defects in chronic papilledema. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1981;217:99-109.
36. Hayreh SS. Pathogenesis of optic disc oedema in raised intracranial pressure. Trans Ophthalmol Soc U K. 1976;96: 404-407.
37. Hayreh SS. Optic disc edema in raised intracranial pressure. V. Pathogenesis. Arch Ophthalmol. 1977;95:1553-1565.
38. Hayreh SS, March W, Anderson DR. Pathogenesis of block of rapid orthograde axonal transport by elevated intraocular pressure. Exp Eye Res. 1979;28:515-523.
39. Tso MO, Hayreh SS. Optic disc edema in raised intracranial pressure. IV. Axoplasmic transport in experimental papillede-ma. Arch Ophthalmol. 1977;95:1458-1462.
40. Corbett JJ, Jacobson DM, Mauer RC, Thompson HS. Enlargement of the blind spot caused by papilledema. Am J Ophthalmol. 1988;105:261-265.
41. Frisen L, Holm M. Visual field defects associated with choroidal folds. In: Glaser JS, ed. Symposium of the University of Miami. Vol 9. St. Louis: Mosby; 1977:248-257.
42. Kim KM, Jeoung JW, Park KH, Kim DM, Ritch R. Relationship between preferred sleeping position and asymmetric visual field loss in open-angle glaucoma patients. Am J Ophthalmol. 2014;157:739-745.
43. Johnson CA, Keltner JL, Cello KE, et al.; and the Ocular Hypertension Treatment Study Group. Baseline visual field characteristics in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2002;109:432-437.
44. Keltner JL, Johnson CA, Beck RW, Cleary PA, Spurr JO, Optic Neuritis Study Group. Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). Control Clin Trials. 1993;14:143-159.
45. Keltner JL, Johnson CA, Cello KE, et al.; and the Ocular Hypertension Treatment Study Group. Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma. 2007;16:665-669.